In conclusion , NVBBs , but not VBBs , determine a lower reduction in cSBP than in pSBP .
However , the difference in treatment-induced SBP amplification changes between NVBB and VBB is nearly abolished after accounting for differences in heart rate changes
β-Blockers are less effective than other antihypertensive drug classes in reducing central systolic blood pressure ( cSBP ) as compared with peripheral SBP ( pSBP ) .
Whether this effect is less pronounced with vasodilating β-blockers ( VBB ) when compared with nonvasodilating β-blockers ( NVBB ) remains unsettled .
Effects of Celiprolol and Bisoprolol on Blood Pressure, Vascular Stiffness, and Baroreflex Sensitivity.
BACKGROUND We tested the hypothesis that celiprolol and bisoprolol have differential effects on blood pressure ( BP ) , flow-mediated dilation ( FMD ) , and vascular stiffness . METHODS We analyzed 102 hypertensives ( mean age : 59±14 years ) who were being treated other than beta-blockers . They were r and omized to receive add-on treatment with either celiprolol 100 - 200 mg ( C group ) or bisoprolol 2.5 - 5 mg ( B group ) , and followed up for 3 months . In addition to clinic , home , and ambulatory BP monitoring , the FMD , radial augmentation index ( AI ) , brachial-ankle pulse wave velocity ( baPWV ) , urine albumin-to-creatinine ratio , and baroreflex sensitivity ( BRS ) were measured at baseline and at the end of the study . RESULTS Compared to the baseline values , home and 24-hour BP were significantly lowered in the third month in both groups ( all Ps < 0.05 ) . Pulse rate ( PR ) and baPWV were reduced ( P < 0.001 ) , and BRS was increased significantly only in the B group ( P = 0.02 ) . Radial AI was unchanged in the C group but was significantly increased in the B group ( P < 0.001 ) . Central BP was significantly reduced in the C group ( P = 0.003 ) but was unchanged in the B group . FMD was significantly increased in both groups ( both P < 0.01 ) . CONCLUSION Bisoprolol achieved the greater reduction of PR and improved BRS and vascular stiffness , whereas , celiprolol reduced the central BP level . In treated hypertensive patients , add-on use of celiprolol may be favorable in uncomplicated stage of hypertension . On the other h and , bisoprolol may be useful in hypertensives with cardiac or vascular diseases who have advanced atherosclerotic changes and sympathetic nervous system activation
In conclusion , NVBBs , but not VBBs , determine a lower reduction in cSBP than in pSBP .
However , the difference in treatment-induced SBP amplification changes between NVBB and VBB is nearly abolished after accounting for differences in heart rate changes
β-Blockers are less effective than other antihypertensive drug classes in reducing central systolic blood pressure ( cSBP ) as compared with peripheral SBP ( pSBP ) .
Whether this effect is less pronounced with vasodilating β-blockers ( VBB ) when compared with nonvasodilating β-blockers ( NVBB ) remains unsettled .